William Blair investment banking’s biopharma team released its quarterly analysis of the sector—“Quarterly Rx: Q2 2023 U.S. Biopharma Recap”—and drew interest from several industry media outlets, including Fierce Biotech.
“After hitting near rock bottom in the summer of 2022, sentiment is now improving across the sector. The second quarter saw ‘meaningful M&A’—16 transactions totaling $29.1 billion in deal value,” the article cited from the group’s report.